Skip to main content

Drug Interactions between maribavir and methadone

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

methadone maribavir

Applies to: methadone and maribavir

Consumer information for this interaction is not currently available.

MONITOR CLOSELY: Coadministration with inhibitors of CYP450 3A4, 2B6, 2C19, 2C9, 2D6 and/or P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of methadone, which is metabolized primarily by CYP450 3A4, 2B6, 2C19, and to a lesser extent by CYP450 2C9 and 2D6 and which is also a substrate of the P-gp efflux transporter. The possibility of prolonged and/or increased pharmacologic effects of methadone, such as central nervous system and respiratory depression should be considered, particularly when an inhibitor is added after a stable dose of methadone is achieved. In addition, high dosages (particularly above 200 mg/day) and serum levels of methadone have been associated with QT interval prolongation and torsade de pointes arrhythmia.

MANAGEMENT: Caution and close clinical monitoring for adverse effects associated with methadone are advised if concurrent use with a CYP450 3A4, 2B6, 2C19, 2C9, 2D6 and/or P-glycoprotein (P-gp) inhibitor. ECG monitoring should be considered for patients on methadone with heart or liver disease; conduction abnormalities; electrolyte disturbances (i.e., hypokalemia, hypomagnesemia); concomitant use of drugs that may cause QT prolongation or electrolyte loss; or concomitant use of CYP450 3A4, 2B6, 2C19, 2C9, 2D6 and/or P-gp inhibitors. Respiratory depression, sedation and pharmacologic response to methadone should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of the CYP450 3A4, 2B6, 2C19, 2C9, 2D6 and/or P-gp inhibitors in patients who are stabilized on their methadone regimen. Patients should be advised to report excessive drowsiness, nausea, or asthenia to their physician, and to seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If taking drugs that also cause CNS-depressant or orthostatic effects, patients should be made aware of the possibility of additive effects with methadone and counseled to avoid activities requiring mental alertness until they know how these agents affect them.

Drug and food/lifestyle interactions

Major

methadone food/lifestyle

Applies to: methadone

Do not use alcohol or medications that contain alcohol while you are receiving treatment with methadone. This may increase nervous system side effects such as drowsiness, dizziness, lightheadedness, difficulty concentrating, and impairment in thinking and judgment. In severe cases, low blood pressure, respiratory distress, fainting, coma, or even death may occur. You should also avoid consuming grapefruit and grapefruit juice, as this may increase the blood levels and effects of oral methadone. High blood levels of methadone can also occasionally cause an irregular heart rhythm that may be serious. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or fast or pounding heartbeats. Do not exceed the dose of methadone prescribed for you or use the medication more frequently or for a longer duration than prescribed by your doctor. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medication without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.